This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01038/identifier/drugbank/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01038/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01038/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB01038
rdf:type
n3:Drug
n3:description
Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.
n3:group
withdrawn
n3:indication
Used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients.
owl:sameAs
n10:DB01038 n11:DB01038
dcterms:title
Carphenazine
adms:identifier
n6:51235 n7:DB01038 n8:PA164750571
n3:mechanismOfAction
A yellow, powdered, phenothiazine antipsychotic agent used in the treatment of acute or chronic schizophrenia. The term "phenothiazines" is used to describe the largest of the five main classes of neuroleptic antipsychotic drugs. These drugs have antipsychotic and, often, antiemetic properties, although they may also cause severe side effects such as akathisia, tardive dyskinesia and extrapyramidal symptoms. Carphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
n3:synonym
Carphenazin Carfenazine
n3:synthesisReference
Tislow, R.F., Bruce, W.F. and Page, J.A.; US. Patent 3,023,146; February 27,1962; assigned to American Home Products Corporation. Sherlock, M.H. and Sperber, N.; US. Patent 2,985,654; May 23, 1961; assigned to Schering Corporation.
n3:IUPAC-Name
n4:271B57B5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B57BB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B57BA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B57B7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B57B8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B57B9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B57B3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B57B4-363D-11E5-9242-09173F13E4C5 n4:271B57B1-363D-11E5-9242-09173F13E4C5 n4:271B57CC-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B57B2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B57C1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B57C2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B57BC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B57BD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B57BF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B57BE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B57C0-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
2622-30-2
n3:category
n3:Bioavailability
n4:271B57C7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B57C9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B57CA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B57CB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B57C6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B57C5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B57C8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B57B6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B57C3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B57C4-363D-11E5-9242-09173F13E4C5